Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy
NCCN announces open registration for a west coast session of NCCN Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business scheduled for July 9 – 10, 2009 in San Francisco. This new educational offering is designed to give pharmaceutical and biotech professionals the rare opportunity to view the oncology space and its current and future operational issues from the provider and payer perspective.
June 8, 2009
FORT WASHINGTON, PA — Industry professionals from pharmaceutical and biotech companies have the opportunity to become students for the day and improve their knowledge of real-world oncology issues at the NCCN Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business scheduled for July 9 – 10, 2009 in San Francisco.
The School of Pharmaceutical & Biotech Business is the first in the NCCN Academy for Excellence & Leadership in Oncology™ series of oncology certificate programs designed by the National Comprehensive Cancer Network (NCCN) to improve the working knowledge of key business, policy, coverage, clinical, reimbursement, informational, and operational issues in oncology and gather valuable insights for developing effective strategies for navigating the various constituencies in cancer care.
“With constant changes to both the clinical aspects and policy impacting the practice of oncology, clinicians are calling for business professionals to be well-versed in relevant information beyond the products they represent,” says William T. McGivney, PhD, Chief Executive Officer, NCCN. “As an authoritative source in oncology care, NCCN is pleased to offer robust, educational programs through NCCN Academy that can help professionals integrate key advances and marketplace changes into their business operations and decisions.”
The School of Pharmaceutical & Biotech Business program features an interactive curriculum that exposes participants to the current environment, trends, and controversies facing the oncology sector and discussion about how key stakeholders, including industry, can create mutually successful working relationships. The scope of the subject matter is far reaching and ranges from the science and business of oncology; to the future of oral chemotherapy and biologics; to frank discussions about cancer policy, coverage and reimbursement, and working effectively with key decision makers.
NCCN Academy offers an introductory curriculum as well as an advanced program; the July program will offer advanced learning for experienced professionals.
Recent reports show that physicians find considerable value in meeting with industry representatives whose knowledge goes beyond product information, making for a more substantive, credible discussion. The School of Pharmaceutical & Biotech Business provides a casual and open learning atmosphere to help professionals better understand the impact of information on data and decisions that influence the availability and use of drugs and biologics in cancer care.
Enrollment is currently open for the west coast session of NCCN Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business scheduled for July 9 – 10 in San Francisco, as well as a session in Chicago scheduled for October 14 – 15. Complete registration information and a syllabus is available at NCCN.org.
Additional Schools within NCCN Academy for Excellence & Leadership in Oncology will include programs for cancer center administrators, clinical executive leaders, and oncology fellows in addition to pharmaceutical and biotech professionals.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.
The NCCN Member Institutions are:
- Fred & Pamela Buffett Cancer Center
- Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
- City of Hope Comprehensive Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
Massachusetts General Hospital Cancer Center
- Duke Cancer Institute
- Fox Chase Cancer Center
- Huntsman Cancer Institute at the University of Utah
- Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- Mayo Clinic Cancer Center
- Memorial Sloan Kettering Cancer Center
- Moffitt Cancer Center
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
- Roswell Park Cancer Institute
- Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
- St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
- Stanford Cancer Institute
- University of Alabama at Birmingham Comprehensive Cancer Center
- UC San Diego Moores Cancer Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- University of Colorado Cancer Center
- University of Michigan Comprehensive Cancer Center
- The University of Texas MD Anderson Cancer Center
- Vanderbilt-Ingram Cancer Center
- Yale Cancer Center/Smilow Cancer Hospital